Fingolimod in Schizophrenia Patients
Completed · Phase 2 · Has a placebo group
Conditions studied: Schizophrenia
In brief
This will be a single site safety and proof of concept study conducted at the Indiana University Psychotic Disorders Program. Forty subjects with schizophrenia or schizoaffective disorders will be randomized 1:1 to double-blind treatment with fingolimod or matched placebo for duration of 8 weeks.
Key facts
- Study ID
- NCT01779700
- Run by
- Indiana University
- People needed
- 40
- Starts
- 2013-01-01
- Expected to finish
- 2016-08-01
- Last updated by the study team
- 2019-04-16
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Center for NeuroImaging — Indianapolis, Indiana, United States
- Prevention and Recovery Center — Indianapolis, Indiana, United States
- Larue D Carter Memorial Hospital — Indianapolis, Indiana, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.